BioCentury | Aug 11, 2014
Company News

Clinuvel, Retrophin deal

...did not produce revenue in 2013. Earlier this year, Retrophin acquired fellow rare disease company Manchester Pharmaceuticals LLC...
BioCentury | Apr 7, 2014
Finance

1Q Stock Wrap-Up: Small but mighty

...company's stock popped again after the company said it would acquire fellow rare disease company Manchester Pharmaceuticals LLC...
BioCentury | Mar 31, 2014
Company News

Manchester Pharmaceuticals LLC, Retrophin deal

...for $62.5 million, including $29.5 million up front, plus undisclosed royalties (see BioCentury, Feb. 17). Manchester Pharmaceuticals LLC...
BioCentury | Feb 17, 2014
Finance

Highlights of weekly biotech stock moves

...$5.25 (49%) to $15.93 on Thursday after saying it will acquire fellow rare disease company Manchester Pharmaceuticals LLC...
BioCentury | Feb 17, 2014
Company News

Manchester Pharmaceuticals, Retrophin deal

Manchester Pharmaceuticals LLC , Fort Collins, Colo. Retrophin Inc. (NASDAQ:RTRX), New York, N.Y. Business: Cardiovascular, Gastrointestinal, Endocrine/Metabolic Retrophin will acquire fellow rare disease company Manchester for $62.5 million, including $29.5 million up front, plus undisclosed royalties....
BioCentury | Feb 14, 2014
Company News

Retrophin jumps on Manchester deal

...$5.25 (49%) to $15.93 on Thursday after saying it will acquire fellow rare disease company Manchester Pharmaceuticals LLC...
Items per page:
1 - 6 of 6
BioCentury | Aug 11, 2014
Company News

Clinuvel, Retrophin deal

...did not produce revenue in 2013. Earlier this year, Retrophin acquired fellow rare disease company Manchester Pharmaceuticals LLC...
BioCentury | Apr 7, 2014
Finance

1Q Stock Wrap-Up: Small but mighty

...company's stock popped again after the company said it would acquire fellow rare disease company Manchester Pharmaceuticals LLC...
BioCentury | Mar 31, 2014
Company News

Manchester Pharmaceuticals LLC, Retrophin deal

...for $62.5 million, including $29.5 million up front, plus undisclosed royalties (see BioCentury, Feb. 17). Manchester Pharmaceuticals LLC...
BioCentury | Feb 17, 2014
Finance

Highlights of weekly biotech stock moves

...$5.25 (49%) to $15.93 on Thursday after saying it will acquire fellow rare disease company Manchester Pharmaceuticals LLC...
BioCentury | Feb 17, 2014
Company News

Manchester Pharmaceuticals, Retrophin deal

Manchester Pharmaceuticals LLC , Fort Collins, Colo. Retrophin Inc. (NASDAQ:RTRX), New York, N.Y. Business: Cardiovascular, Gastrointestinal, Endocrine/Metabolic Retrophin will acquire fellow rare disease company Manchester for $62.5 million, including $29.5 million up front, plus undisclosed royalties....
BioCentury | Feb 14, 2014
Company News

Retrophin jumps on Manchester deal

...$5.25 (49%) to $15.93 on Thursday after saying it will acquire fellow rare disease company Manchester Pharmaceuticals LLC...
Items per page:
1 - 6 of 6